Rofecoxib Articles
Merck & Co and Johnson & Johnson settlements
20 January 2012
Merck & Co to pay $950 million for illegal marketing of Vioxx
23 November 2011
Australian Judge rules against Merck & Co’s Vioxx, saying the pain drug is not fit for sale
5 March 2010
Merck & Co settles Vioxx law suits, agreeing to strengthen drug safety procedures and pay $12.2 million legal fees
11 February 2010
Court upholds Merck & Co Canada Vioxx appeal
1 April 2009
Merck & Co targeted by federal prosecutors over Vioxx
30 March 2009
Data on withdrawn drugs was faked; says hospital
16 March 2009
NicOx shares up 44% on strong late-stage data
10 November 2008
Pharma "a nice juicy target" for "Pres" Obama, DTC expert claims, TV and social media hit
20 October 2008
Florida AG sues Merck & Co over Vioxx
13 October 2008
Merck & Co's Vioxx lawsuit reinstated, firm may appeal decision
15 September 2008
France finally approves Merck & Co
28 July 2008
Merck & Co to start $4.85B Vioxx payout
28 July 2008
FDA slows down approvals, firms claim
7 July 2008
Merck & Co wins Vioxx compensation case
16 June 2008
Merck & Co wins in Vioxx case appeal
9 June 2008
Merck & Co in $58M deal with 29 states
26 May 2008
Merck & Co 1Q results saved by AZ payout
28 April 2008
NicOx' FY 2007 income doubles, big year ahead
10 March 2008
Merck & Co reports on Vioxx law suits
10 March 2008
Merck & Co's $671M rebate settlement
18 February 2008
Vioxx costs see Merck & Co swing to $1.6B loss
4 February 2008
Merck & Co Vioxx settlement likely
21 January 2008
US new drug approvals hit 24-year low
14 January 2008
Novartis' Prexige withdrawn by UK, German and Austrian regulators on liver safety fears
26 November 2007
Stock Commentary - New York week to Nov 12, 2007
19 November 2007
Merck & Co to pay $4.85B to resolve Vioxx suits
19 November 2007
France
5 November 2007
Merck & Co's 3rd-qtr 2007 sales jump 12%
29 October 2007
NJ hIgh court denies Vioxx class action
17 September 2007
Merck & Co's 2nd-qtr 2007 EPS jumps 12%
30 July 2007
Merck & Co asks for cut of $47.5M Vioxx award
23 July 2007
FDA OK of label does "not avert claims"
9 July 2007
Stock Commentary - New York week to April 16, 2007
23 April 2007
Federal court dismisses Vioxx securites call action
23 April 2007
Merck & Co ups earnings guidance
23 April 2007
FDA considers Merck & Co's Arcoxia for approval
16 April 2007
Another Vioxx win for Merck & Co
2 April 2007
Merck & Co ordered to pay $47.5M in Vioxx case
19 March 2007
Merck & Co's 4th-qtr income plunges 58%
5 February 2007
Plaintiff dismisses Vioxx law suit ahead of trial
29 January 2007
Latest Vioxx plaintiff fails to prove case
29 January 2007
ULT files Arthroleve patent
22 January 2007
FDA approvals to rise by 2010, says Tufts
22 January 2007
World's "10 most promising" treatments
15 January 2007
Merck & Co wins 12th Vioxx case
18 December 2006
Australia's PBS growth drops below inflation
18 December 2006
Merck & Co's reaffirms cautious 2006 EPS
18 December 2006
Merck & Co switches DTC marketing focus
11 December 2006
US federal judge denies class-action status to Vioxx law suits
27 November 2006
Stock Commentary - New York week to Nov 20, 2006
27 November 2006
Merck & Co wins latest Vioxx damages case
27 November 2006
Merck & Co completes response to FDA's questions on Arcoxia, but narrows the scope of indications
20 November 2006
No FDA calls for CV risk trials of naproxcinod
20 November 2006
Merck & Co's 3rd-qtr income down 38% to $904.6 million on flat sales and higher costs
30 October 2006
Drug ad spending rose 9% in 1st half 2006
30 October 2006
US Judge orders Merck & Co to disclose Vioxx trial costs
23 October 2006
Standard US NME appros suffering
16 October 2006
UK patients barred from US Vioxx law suits
16 October 2006
Merck & Co delays 2007 filing of MK-524B on formulation issue, pre-2009 launch unlikely
9 October 2006
Stock Commentary - Europe - week to Oct 2, 2006
9 October 2006
FDA "more cautious" about drug approvals
9 October 2006
US counterfeit drug scam used Internet spam
9 October 2006
Merck & Co cleared in 10th Vioxx suit
2 October 2006
PSC accuses Merck & Co of "jury tampering"
18 September 2006
Incentives needed for postmarketing studies
18 September 2006
Judge calls $50M damages in Vioxx case "excessive"
4 September 2006
Encouraging CV profile for Merck & Co's Arcoxia
4 September 2006
Negative news for Merck & Co on Vioxx cases
28 August 2006
Californian jury rejects Vioxx case
7 August 2006
France's reimbursable drug sales grew 6.7%
7 August 2006
NJ jury votes for Merck & Co on Vioxx
24 July 2006
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
